The Health Resources and Services Administration today launched a new website that organizations participating in the 340B Drug Pricing Program can use to determine the maximum prices drug companies can charge them for medications sold under the program.

“The AHA is pleased that, in response to our successful lawsuit, HRSA today launched a new website to shine needed light on 340B drug pricing, which the government has found lacking,” said AHA Executive Vice President Tom Nickels. “This website will help make sure hospitals participating in the program are not being overcharged by drug companies and that instances of price gouging can be uncovered and penalties enforced. As prescription drug prices continue to skyrocket, the 340B program is as crucial as ever in helping hospitals provide access to health care services for patients in vulnerable communities.”

HRSA last November issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B program. The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems last September filed a lawsuit to force implementation of the rule. 
 

Related News Articles

Headline
The AHA May 1 expressed concerns (LINK) to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from…
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory…